Skip to content

    GPT Healthcare

    GPTHEALTH
    Healthcare·12 Feb 2025
    Management Summary

    GPT Healthcare delivered a resilient Q3 FY25 performance with 6% YoY growth in both revenue and PAT, reaching INR 102 crores and INR 12 crores respectively. The company maintained a 22% EBITDA margin for the nine-month period and significantly reduced finance costs by 55%. Despite external challenges impacting overall FY25 growth, GPT Healthcare is actively expanding its footprint with new hospitals in Raipur and Jamshedpur, while strategically improving ARPOB and operational efficiency through reduced ALOS.

    Highlights

    5
    • Revenue from operations for Q3 FY25 was INR 102 crores, marking a 6% year-on-year growth.

    • Profit After Tax (PAT) for Q3 FY25 increased by 6% year-on-year to INR 12 crores.

    • The 9-month FY25 EBITDA margin stood at 22%, with EBITDA increasing by 2% to INR 69.6 crores.

    • Finance costs saw a significant reduction of 55% due to effective debt management.

    • Average Revenue Per Occupied Bed (ARPOB) for 9 months FY25 increased by 21% to INR 31,850, driven by a focus on complex treatments and insurance rate renewals.

    Concerns

    4
    • Overall growth for FY25 has been flat compared to initial guidance due to unforeseen external factors like the RG Kar incident, Bangladesh dispute, and Tripura floods.

    • Occupancy levels have seen a slight dip due to the company's strategic focus on reducing the Average Length of Stay (ALOS), despite an increase in inpatient volumes.

    • International patient volumes from Bangladesh, historically contributing 10% to Agartala's volume, were significantly impacted in Q3 FY25 due to a political dispute.

    • The Ranchi hospital project is experiencing exceptional delays due to developer and government approvals, necessitating the pursuit of an alternative in Jamshedpur.

    What Changed3

    vs Q4 FY25

    Guidance items16 → 9 (-7)Risks discussed3 → 4 (+1)Q&A highlights6 → 8 (+2)
    Key financials

    Metrics

    6

    Periods

    2

    Headline

    4
    • Revenue
      ₹102 Cr
      YoY+6%
    • PAT
      ₹12 Cr
      YoY+6%
    • EBITDA
      ₹23 Cr
    • EBITDA Margin
      22.7%

    9M FY25

    2
    • ARPOB
      ₹36,700
    • ALOS
      3.54 days

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    asset-light rental-based model for Raipur

    Debt

    Debt disclosed

    M&A

    Ongoing hospitals

    acquisition · Other

    Liquidity

    Cash ₹45 crores

    Guidance & targets

    9
    CategoryTargetPriority
    Capacity
    Total bed capacity
    1,000 beds
    High
    Capacity
    Jamshedpur Hospital beds
    150 beds
    High
    Operations
    ILS Hospital Raipur commencement
    early April
    High
    Operations
    Jamshedpur Hospital commissioning
    October of 2026
    High
    Capex
    Jamshedpur Hospital outlay
    INR 65 crores
    High
    Revenue
    Revenue CAGR
    15%
    High
    Profitability
    EBITDA margin
    22% to 23%
    High
    ARPOB
    ARPOB increase
    7% to 8%
    Medium
    Operational Efficiency
    Dum Dum ALOS reduction
    0.25 days
    Medium

    Raipur Hospital Commencement

    early April
    CurrentUnder construction, INR 55 crores investment
    TargetCommercial operations

    Why it matters

    New capacity addition and revenue contribution from a key expansion project.

    ILS Hospital Raipur, a 152-bed facility is expected to commence operations in early April.

    How to verify

    detailed_narrative[title='New Hospital Expansion'].content

    Risks & concerns

    4
    RiskSeverity

    External factors impacting growth

    FY25 growth impacted by RG Kar incident, Bangladesh dispute, and Tripura floods.Management acknowledged

    high

    International patient volume reduction from Bangladesh

    10% of Agartala's patient volume from Bangladesh impacted in Q3 due to political dispute.Management acknowledged

    high

    Ranchi project delays

    Project facing exceptional delays due to developer and government approvals, leading to Jamshedpur as an alternative.Management acknowledged

    medium

    Slight dip in occupancy

    Due to strategic focus on reducing Average Length of Stay (ALOS), despite increasing inpatient volumes.Management acknowledged

    low

    Q&A highlights

    8

    “Yes, the growth in ARPOB has been a culmination of various factors. It is definitely an impact of case mix. Across all our hospitals, we are focusing on more complex treatments, including transplants, including robotic knee surgeries and other higher tertiary care treatment. So that has definitely impacted the ARPOB. That combined with insurance rate renewals, which have happened in the past year have led to the increase in ARPOB.”

    Clarifies the strategic shift towards higher-value treatments and the role of insurance renewals in ARPOB improvement.

    asked by Aman from Phillip Capital

    3 min read6 chapters

    Detailed Narrative

    01

    Q3 and 9 Months FY25 Financial Performance

    GPT Healthcare reported a 6% year-on-year increase in revenue from operations for Q3 FY25, reaching INR 102 crores. Profit After Tax (PAT) for the quarter also grew by 6% to INR 12 crores. For the nine-month period, PAT stood at INR 37 crores with a 12% margin, while EBITDA margin was 22%, reflecting a 2% increase in EBITDA to INR 69.6 crores. The company's ARPOB for 9 months FY25 was INR 36,700, and the Average Length of Stay (ALOS) reduced to 3.54 days from 3.98 days in the prior year.

    02

    New Hospital Expansion and Capacity Targets

    The company is steadfast in its goal to become a 1,000-bed hospital chain within the next 2 to 3 years. A new 152-bed ILS Hospital Raipur, involving a INR 55 crore investment and an asset-light rental model, is expected to commence operations in early April. Additionally, an MOU has been signed for a third hospital in Jamshedpur, which will have a capacity of 150 beds with an estimated outlay of INR 65 crores, projected to be operational by October 2026. These expansions are crucial for scaling operations and reaching underserved communities.

    03

    Operational Efficiency and Case Mix Improvement

    GPT Healthcare is actively working to improve operational metrics, including a focus on reducing the Average Length of Stay (ALOS). For instance, Dum Dum Hospital's ALOS reduced from 5.29 days to 4.57 days year-on-year, and the company aims for a further 0.25-day reduction. This strategy, combined with a shift towards more complex treatments like transplants and robotic surgeries, has led to an increase in ARPOB across hospitals, with ILS Salt Lake seeing a 16.6% rise to INR 39,200 for 9M FY25. While this has led to a slight dip in occupancy, inpatient volumes have increased overall.

    04

    Market Strategy and Geographic Focus

    The company's expansion into Raipur is driven by the low bed-to-population ratio in Chhattisgarh (11-12 beds per 10,000) and limited national player presence. GPT Healthcare plans to cater to the entire state of Chhattisgarh and Odisha, focusing on cash and insurance patients. In terms of medical tourism, the company continues to focus on Bangladesh, which historically contributed 10% of Agartala's patient volumes, and is also increasing its focus on Bhutan, despite recent impacts from geopolitical disputes in Bangladesh.

    05

    Capital Allocation and Debt Management

    GPT Healthcare has demonstrated strong debt management, resulting in a 55% reduction in finance costs. The company currently holds approximately INR 45 crores in cash on its balance sheet and is considered net debt-free. Management indicated a willingness to take on judicious debt for future growth initiatives without equity dilution, highlighting sufficient headroom. The company is also actively evaluating acquisition opportunities for ongoing hospitals in cities like Guwahati, Bhubaneswar, and Patna to accelerate bed capacity expansion.

    06

    Challenges and Future Outlook

    Despite reaffirming its long-term target of 15% CAGR revenue growth and maintaining EBITDA margins between 22% to 23% over the next 2-3 years, FY25 growth has been flat due to unforeseen external factors. These include the RG Kar incident, the Bangladesh dispute, and floods in Tripura, which impacted overall productivity. The Ranchi project is also facing significant delays, leading the company to pursue Jamshedpur as a safeguard. Management expressed confidence in returning to growth parameters soon.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.